Susan Jones

ImmuRx, Inc. develops adjuvant platforms for the treatment of cancer and infectious disease. Its product includes CD40 compound, an antibody. The company was founded by Randolph J. Noelle and Ross Kedl in 2005 and is headquartered in Lebanon, NH.

Part of OPKO Health, Inc., Waratah Pharmaceuticals, Inc. develops pharmaceutical products. The company is based in Calgary, Canada. The Canadian company was founded by Susan Dana Jones. Waratah Pharmaceuticals was acquired by Transition Therapeutics, Inc., part of OPKO Health, Inc. from September 01, 2016 on January 28, 2002 for $15.46 million.

Serenex, Inc. operates as a biotechnology company that develops drugs for tumors and cancers of the blood and bone marrow. Its products include drugs for chemotherapy treatments as well as inhibitor compounds. Serenex was founded by George Young and Timothy Haystead in 2000 and is headquartered in Durham, NC.

Gene Solutions LLC conducts therapeutic drug discovery research for central nervous system diseases by utilizing its proprietary mitochondrial genomic targets. It delivers mitochondrial therapeutic solutions and choices for pharmaceutical and biotechnology companies to enhance their drug pipelines in the field of Alzheimer’s, Parkinson’s, and schizophrenia diseases. The company was founded in 2006 by William Davis Parker Jr. and Edward P Connell and is headquartered in Charlottesville, VA.

Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.